Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.22 +1.4%	$1.99	$1.33 ▼ $3.58	$103.17M	0.74	111,887 shs	44,535 shs
BMEA Biomea Fusion	$1.92 +3.2%	$1.77	$1.29 ▼ $13.07	$110.69M	-0.14	643,080 shs	1.58 million shs
DARE Dare Bioscience	$2.03 +0.5%	$2.37	$1.83 ▼ $9.19	$27.23M	1.11	227,242 shs	109,634 shs
EQ Equillium	$1.82 -4.7%	$0.68	$0.27 ▼ $2.26	$113.65M	1.15	23.43 million shs	1.41 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-7.59%	+5.80%	+10.27%	+12.02%	-27.24%
BMEA Biomea Fusion	+1.64%	+4.49%	+3.33%	+24.83%	-76.28%
DARE Dare Bioscience	-0.98%	-1.94%	-20.78%	-29.86%	-41.28%
EQ Equillium	-2.05%	+67.54%	+328.64%	+451.86%	+83.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	3.014 of 5 stars	3.5	5.0	2.7	1.7	0.0
BMEA Biomea Fusion	3.6954 of 5 stars	4.6	3.0	2.2	2.5	0.6
DARE Dare Bioscience	2.4848 of 5 stars	3.5	5.0	2.6	0.0	0.0
EQ Equillium	0.9728 of 5 stars	1.0	5.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.00	215.32% Upside
BMEA Biomea Fusion	3.15	Buy	$15.73	719.13% Upside
DARE Dare Bioscience	3.00	Buy	$12.00	491.13% Upside
EQ Equillium	2.00	Hold	$1.00	-45.05% Downside

Current Analyst Ratings Breakdown

Latest DARE, EQ, ADAG, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	BMEA Biomea Fusion	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
8/15/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	1,045.84	N/A	N/A	$0.80 per share	2.78
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.46 per share	N/A
DARE Dare Bioscience	$10K	2,736.44	N/A	N/A	($0.94) per share	-2.16
EQ Equillium	$41.10M	2.63	N/A	N/A	$0.08 per share	22.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	-$138.43M	-$3.03	N/A	N/A	N/A	N/A	-243.95%	-140.74%	11/4/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$2.14	N/A	N/A	N/A	N/A	N/A	-103.70%	11/13/2025 (Estimated)
EQ Equillium	-$8.07M	-$0.56	0.00	N/A	N/A	-19.62%	-139.56%	-90.56%	11/12/2025 (Estimated)

Latest DARE, EQ, ADAG, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	($0.02) million
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.29	2.30
BMEA Biomea Fusion	N/A	3.68	3.68
DARE Dare Bioscience	N/A	0.34	0.34
EQ Equillium	N/A	1.65	1.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
BMEA Biomea Fusion	96.72%
DARE Dare Bioscience	6.70%
EQ Equillium	27.05%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
BMEA Biomea Fusion	18.42%
DARE Dare Bioscience	4.80%
EQ Equillium	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
BMEA Biomea Fusion	50	59.51 million	48.55 million	Optionable
DARE Dare Bioscience	30	13.48 million	12.83 million	Not Optionable
EQ Equillium	40	59.50 million	40.70 million	Not Optionable

DARE, EQ, ADAG, and BMEA Headlines

Recent News About These Companies

Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC

August 28 at 6:06 PM | seekingalpha.com

Equillium price target lowered to $4 from $8 at Jefferies

August 20, 2025 | msn.com

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

August 11, 2025 | finance.yahoo.com

Equillium Secures $30 Million in Private Placement

August 11, 2025 | tipranks.com

Equillium Shares Drop 12.4% After Unveiling Cryptocurrency Treasury Strategy

August 4, 2025 | msn.com

Spotlight On 3 Promising Penny Stocks With Over $20M Market Cap

August 4, 2025 | finance.yahoo.com

Equillium stock falls after announcing cryptocurrency treasury strategy

August 4, 2025 | au.investing.com

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

August 4, 2025 | businesswire.com

Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

July 11, 2025 | finance.yahoo.com

Equillium, Inc. (EQ) stock price, news, quote & history - Yahoo Finance

June 26, 2025 | nz.finance.yahoo.com

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

June 14, 2025 | medindia.netM

Equillium expands equity incentive plan by 1.78 million shares

May 24, 2025 | investing.com

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025 | finance.yahoo.com

Equillium advancing new AhR modulator

May 3, 2025 | bioworld.comB

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025 | finance.yahoo.com

Blood Cancer Data Ignore Sex; Cancer Biosimilars Take Off; Mixed Prevention News

April 26, 2025 | msn.com

Equillium says FDA declines Breakthrough Therapy designation for itolizumab

April 25, 2025 | markets.businessinsider.com

Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’

April 25, 2025 | markets.businessinsider.com

FDA declines itolizumab accelerated approval, says Equillium

April 25, 2025 | thepharmaletter.comT

Equillium shares fall following FDA feedback

April 24, 2025 | in.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DARE, EQ, ADAG, and BMEA Company Descriptions

Adagene NASDAQ:ADAG

$2.22 +0.03 (+1.37%)

Closing price 03:59 PM Eastern

Extended Trading

$2.23 +0.01 (+0.27%)

As of 05:33 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Biomea Fusion NASDAQ:BMEA

$1.92 +0.06 (+3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$1.90 -0.02 (-1.30%)

As of 07:56 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Dare Bioscience NASDAQ:DARE

$2.03 +0.01 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+0.74%)

As of 06:45 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Equillium NASDAQ:EQ

$1.82 -0.09 (-4.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 -0.02 (-0.82%)

As of 07:59 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time